Improving healthcare for all, a new training platform for the bioproduction sector

Run by bioMérieux, Novasep, Sanofi and Servier, the digital training platform delivers courses covering the entire bioproduction chain.

25 May 2022

The first two courses went online in April 2022. A total of 13 training programs cover the whole bioproduction chain from the design phase to the delivery of the product to the patient. is a fully digital solution, a few modules will also be available in person at the future pedagogical resources center at Sanofi’s facility in Vitry-sur-Seine, near Paris. 

The courses are offered in two languages, English and French. They were co-designed with specialists in biotechnology training (EASE, ENSTBB-Bordeaux INP, CPE Lyon, the ESTBB, IFIS, the IMT group, MabDesign, Sup’Biotech) and digital technology (Accenture, Atos, Bearing Point, Capgemini, Domoscio, IBM, Microsoft). is inspired by the flight simulators used to train pilots. Learners are provided with a broad spectrum of digital tools that reproduce as faithfully as possible the actions and situations encountered in the workplace: digital twins, serious games, immersive reality, virtual reality, augmented reality, etc.

“The purpose of is to support the bioproduction sector and meet its training needs with a range of differentiating offers combining science, new technologies, and data analysis, hence providing the most up-to-date courses possible,” explains Karim Vissandjee, Managing Director of Campus Biotech Digital.

The platform addresses the critical public health challenge of training and upskilling employees in the bioproduction sector. An estimated 30 to 40,000 jobs will be created in the sector in Europe over the next 10 years (in France, the number of jobs will double from 10,000 to 20,000). 

France has set its sights on becoming the top European country for health innovation and is therefore investing over €7 billion under its 2030 Health Innovation Plan. One of the goals is to manufacture at least five biomedicines in France by 2030. At present, only two of the 76 biomedicines approved for use in Europe are made in France. “We also want to build cooperation between the various actors involved in bioproduction in France and Europe (research labs, SMEs, schools, businesses, etc.) to optimize the discovery of new therapies,” explains Karim Vissandjee. 

The courses, which lead to a formal qualification, are aimed at first-time learners such as employees seeking to reskill. They comprise two levels: basic and expert. Students have four months to complete the course, which contains 15 to 20 hours of exercises and modules. They are then given a badge that qualifies them to work on a new production line.

What are you looking for?